MPS Completes Acquisition of HighWire Press to Accelerate Platform Business
1.7.2020 20:30:00 EEST | Business Wire | Press release
MPS Limited (MPS), a leading provider of content, learning, and platform solutions, has announced today that they have completed the acquisition of HighWire Press. HighWire has long been an industry thought leader and has championed many of the digital standards and initiatives that have shaped modern scholarly publishing.
MPS and HighWire share an ethos of embedding flexibility into publishing solutions through strategic partner programs and have grown and evolved their respective businesses organically, through third-party integrations, and selective acquisitions.
The combination presents a significant opportunity for MPS’ and Highwire’s customers. Increased resources, more comprehensive platform offerings, and a broader partner and distribution network are just some of the benefits.
“The acquisition of HighWire further deepens our commitment to the Academic/STM community, whom we were founded to serve back in 1970,” said Rahul Arora, CEO and Managing Director of MPS Limited. “We will further invest, build, and grow HighWire to advance global discovery, research, and innovation, which aligns with our overarching mission of Making Learning Smarter.”
“In the year that HighWire celebrates its 25th anniversary and MPS its 50th, we are excited to draw upon that wealth of knowledge to continue to shape the future of digital content,” said Tim Bacci, CEO of HighWire. “There is clear alignment with our core company values, and we are looking forward to leveraging the synergies as a result of our collective product suites that will prove beneficial to customers.”
About MPS Limited
MPS was established as a subsidiary of Macmillan Limited in 1970 to change the way the world learns. After a change of majority stake in 2011-12 and with an entrepreneurial mindset, MPS developed significant momentum as a result of consistent reinvestment in the business and six acquisitions in six years; the first five were acquisitions of scale while the sixth was an acquisition of scope.
MPS now provides platform, learning, and content solutions and is a global partner to the world’s leading enterprises, publishers, learning companies, and content aggregators. MPS is listed on major Indian stock exchanges; nearly 2,500 associates power MPS across seven development centers in India, two subsidiaries in Europe, and five client offices in the US. MPS has been at the forefront of market changes, introducing new ways of learning and driving impact from each learning experience through engaging content and advanced platforms.
About HighWire
HighWire is an industry-leading global provider of digital publishing tools and platform solutions across all aspects of the publishing life cycle, including content management and hosting, e-commerce, analytics, access and identity management, manuscript submission and tracking.
HighWire was born out of Stanford University, shaped the early stages of digital scholarly publishing, and is now celebrating its 25th year since it was founded. This combination of deep domain publishing and academic expertise makes HighWire the technology partner of choice for the leading global commercial and academic publishers.
For more information, please visit highwirepress.com and follow us on Twitter, LinkedIn, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005809/en/
Contact information
Natalie Guest
Marketing Manager
nguest@highwirepress.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom